Explore science that's focused on your needs
KOVALTRY® is manufactured using state-of-the-art technology
Unmodified, full length rFVIII In unmodified, full length Factor VIII, no other molecules have been added to the protein structure, and no parts of the Factor VIII protein have been removed. product designed to closely match your body's natural Factor VIII1
Unmodified, full length rFVIII In unmodified, full length Factor VIII, no other molecules have been added to the protein structure, and no parts of the Factor VIII protein have been removed. product designed to closely match your body's natural Factor VIII1
HSP70, a chaperone protein, is used to improve folding During a protein's development, folding occurs so the protein is shaped into its correct, three-dimensional structure.2 of the Factor VIII protein1
HSP70, a chaperone protein, is used to improve folding During a protein's development, folding occurs so the protein is shaped into its correct, three-dimensional structure.2 of the Factor VIII protein1
No human- or animal-derived raw materials are added in the cell culture, purification, or formulation processes1
No human- or animal-derived raw materials are added in the cell culture, purification, or formulation processes1
Passes through a microscopic filter (20 nm) to remove viruses1
Passes through a microscopic filter (20 nm) to remove viruses1
KOVALTRY®
KOVALTRY®
HSP70=heat shock protein 70.
nm=nanometer.
HSP70=heat shock protein 70.
nm=nanometer.
INDICATION FOR KOVALTRY®
KOVALTRY® is a medicine used to replace clotting factor (Factor VIII or antihemophilic factor) that is missing in people with hemophilia A.
KOVALTRY is used to treat and control bleeding in adults and children with hemophilia A. KOVALTRY can reduce the number of bleeding episodes in adults and children with hemophilia A when used regularly (prophylaxis). Your healthcare provider may give you KOVALTRY when you have surgery.
KOVALTRY is not used to treat von Willebrand Disease.
IMPORTANT SAFETY INFORMATION
You should not use KOVALTRY if you are allergic to rodents (like mice and hamsters) or any ingredients in KOVALTRY.
Tell your healthcare provider if you have heart disease or are at risk for heart disease.
The common side effects of KOVALTRY are fever, headache, and rash, in addition to inhibitors in patients who were not previously treated or minimally treated with Factor VIII products.
Your body may make antibodies, called “inhibitors” against KOVALTRY, which may stop KOVALTRY from working properly. If your bleeding is not adequately controlled, it could be due to the development of Factor VIII inhibitors. Consult with your healthcare provider to make sure you are carefully monitored with blood tests for the development of inhibitors to Factor VIII.
Allergic reactions may occur with KOVALTRY. Call your healthcare provider right away and stop treatment if you get tightness of the chest or throat, dizziness, decrease in blood pressure, and nausea.
Tell your healthcare provider about any side effect that bothers you or that does not go away.
Call your healthcare provider right away if bleeding is not controlled after using KOVALTRY.
For additional important risk and use information, please see full Prescribing Information.
References: 1. KOVALTRY® [prescribing information]. Whippany, NJ: Bayer HealthCare LLC; 2021. 2. Cooper G, Hausman R. The Cell: A Molecular Approach. 4th ed. Sunderland, MA: Sinauer Associates; 2007.
